488705-01-7

Basic information

• Product Name: 7-[benzyloxymethyl]-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one
• Synonyms: 7-[benzyloxymethyl]-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one
• CAS NO: 488705-01-7
• Molecular Weight: 445.348
• Mol File: 488705-01-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 7-[benzyloxymethyl]-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[benzyloxymethyl]-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one(488705-01-7)
• EPA Substance Registry System: 7-[benzyloxymethyl]-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one(488705-01-7)

Safety Data

• Hazardous Substances Data: 488705-01-7(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 488705-93-7 1-(benzyloxymethyl)-4-[(2,4-dichlorophenyl)amino]-2-ethyl-N-methyl-1H-imidazole-5-carboxamide 
• 5310-94-1 N-(2,4-dichlorophenyl)-N'-methyl-urea 
• 144-55-8 sodium hydrogencarbonate 
• 488705-91-5 7-(benzyloxymethyl)-3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione 
• 488705-85-7 5,6-diamino-1-(2,4-dichlorophenyl)-3-methyl-2,4(1H,3H)-pyrimidinedione 
• 488705-81-3 6-amino-1-(2,4-dichlorophenyl)-3-methyl-2,4(1H,3H)-pyrimidinedione 
• 2612-57-9 2,4-dichlorophenyl isocyanate 
• 3587-60-8 Benzyloxymethyl chloride 
• 488705-87-9 3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione 
• 488705-83-5 6-amino-1-(2,4-dichlorophenyl)-3-methyl-5-nitroso-2,4(1H,3H)-pyrimidinedione 

Downstream Products

• 488705-95-9 3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-one 

Relevant articles and documents

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6H- purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives as corticotropin-releasing factor1 receptor antagonists

A growing body of evidence suggests that CRF1 receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2, 6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF1 receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF1 antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.